Thinking Clearly about Association Studies (Risk Factors and Causal Salad included)

For the example I gave, worth noting: Tazverik (tazemetostat) was voluntarily withdrawn from all global markets and indications on March 9, 2026, due to safety concerns. For dire indications with no effect therapy, arguably best supportive care can be a control that will be acceptable to some patients and to IRB reviewers.